North American sales accounted for 95% of Health Robotics’ new contract revenue, as the company expanded its worldwide success also within the US Federal Government, winning contract awards from both for the
Gaspar DeViedma, Health Robotics’ Executive Vice President and Board Member, stated: “Health Robotics has significantly outperformed all of its prior years’ results with 174 new contracts [52 Robots] YTD in 2013, compared to 79 new sales YTD in 2012. In
With over 115 i.v.STATION platform 2nd Generation Robots and more than 200 i.v.SOFTs under contract worldwide, Health Robotics has now tripled the installations of its first generation  technology, including over 30 installations under contract for patient-specific HL7 interfaces to Epic, Cerner, Siemens, McKesson,
About Health Robotics:
Founded in 2006 and now reaching 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing more than 500 hospital installations in 5 continents with the only fully-integrated Robotics based technology, IV Workflow, and manual compounding software automation solutions. Health Robotics’ second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies 1, 2, 3] to greatly contribute to ease hospitals’ growing pressures to improve patient safety1, increase throughput, and contain costs1, 3. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics’ medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug1 and diluent1 exchange errors, improve drug potency2, decrease other medical mistakes and sterility risks, work more efficiently1, 3, reduce waste and controlled substances’ diversion, reduce pharmacy technician upper-limb injuries3, and diminish the gap between rising patient volume/acuity and scarce nursing and pharmacy staff.
1 Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs.
2 Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte,
3 Comparing the upper limb disorder risks associated with manual and automated cytotoxic compounding. McLeod, Zochowska, Leonard, Crow, Jacklin, Dean, Franklin.
Source: Health Robotics
Most Popular Stories
- NSA Defends Global Cellphone Tracking Legality
- Top Websites for U.S. Hispanics
- Networks Vie for U.S. Hispanic TV Viewers
- Ad Counts Rise in 2013 for Hispanic Magazines
- Apple Wants Samsung to Pay $22M for Patent Dispute Legal Bills
- Starbucks Gets Grinchy; No Gingerbread Lattes for Tampa Customers
- Saab Gets Back into the Game; U.S. Auto Sales Soar
- Jobs Report Brings Cheer As Unemployment Drops to Five-year Low
- Apple Paid Its Lawyers More Than $60MM to Defeat Samsung in Court
- US Consumer Borrowing Rose $18.2B in Oct.